ID   UMC-11
AC   CVCL_1784
SY   UMC11; NCI-UMC-11
DR   CLO; CLO_0009483
DR   EFO; EFO_0002386
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-5975
DR   BioSample; SAMN03473023
DR   Cell_Model_Passport; SIDM01183
DR   ChEMBL-Cells; CHEMBL3308343
DR   ChEMBL-Targets; CHEMBL1075606
DR   Cosmic; 687835
DR   Cosmic; 909779
DR   Cosmic; 1879414
DR   Cosmic; 1995662
DR   Cosmic; 2433549
DR   Cosmic-CLP; 909779
DR   DepMap; ACH-001417
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 909779
DR   GEO; GSM784236
DR   GEO; GSM827360
DR   GEO; GSM1670566
DR   IARC_TP53; 27266
DR   LINCS_LDP; LCL-1154
DR   PharmacoDB; UMC11_1644_2019
DR   Progenetix; CVCL_1784
DR   Wikidata; Q54991072
RX   PubMed=1311061;
RX   PubMed=1563005;
RX   PubMed=8806092;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=25485619;
RX   PubMed=26087898;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu536fs*14 (c.1606_1612delCTAGACG); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp228fs*19 (c.681delT) (p.S227fs); Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.55%; Native American=0%; East Asian, North=1.07%; East Asian, South=0.34%; South Asian=2.02%; European, North=69.48%; European, South=26.54% (PubMed=30894373).
CC   Misspelling: UNC-11; In PubMed=1563005.
ST   Source(s): ATCC; Cosmic-CLP; DepMap; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 8,13
ST   D16S539: 11,12
ST   D18S51: 14
ST   D21S11: 31.2
ST   D3S1358: 14
ST   D5S818: 11
ST   D7S820: 9,11
ST   D8S1179: 13,15
ST   FGA: 20,24
ST   Penta D: 13
ST   Penta E: 18,19
ST   TH01: 6,9.3
ST   TPOX: 9,11
ST   vWA: 14,15
DI   NCIt; C4038; Lung carcinoid tumor
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 31
//
RX   PubMed=1311061;
RA   Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D., D'Amico D.,
RA   Bodner S., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D.,
RA   Gazdar A.F.;
RT   "p53 gene mutations in non-small-cell lung cancer cell lines and their
RT   correlation with the presence of ras mutations and clinical
RT   features.";
RL   Oncogene 7:171-180(1992).
//
RX   PubMed=1563005;
RA   Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.;
RT   "Neuromedin B is present in lung cancer cell lines.";
RL   Cancer Res. 52:2732s-2736s(1992).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26087898; DOI=10.1016/j.cancergen.2015.04.002;
RA   Boora G.K., Kanwar R., Kulkarni A.A., Pleticha J., Ames M.,
RA   Schroth G., Beutler A.S., Banck M.S.;
RT   "Exome-level comparison of primary well-differentiated neuroendocrine
RT   tumors and their cell lines.";
RL   Cancer Genet. 208:374-381(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//